Loading…
Guardant Health, Inc. is projected to rise to $242.62 by 2027, a +52% move from its current price of $160.05. GH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $154.87 | $160.06 | $165.43 | +0.01% |
| Jul 14 | $152.78 | $160.07 | $167.71 | +0.02% |
| Jul 15 | $151.20 | $160.09 | $169.49 | +0.02% |
| Jul 16 | $149.88 | $160.10 | $171.01 | +0.03% |
| Jul 17 | $148.73 | $160.11 | $172.36 | +0.04% |
| Jul 18 | $147.70 | $160.12 | $173.59 | +0.05% |
| Jul 19 | $146.76 | $160.14 | $174.73 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $146.76 | $160.14 | $174.73 | +0.05% |
| Week 2 | $141.63 | $160.22 | $181.26 | +0.11% |
| Week 3 | $137.83 | $160.31 | $186.45 | +0.16% |
| Week 4 | $134.72 | $160.39 | $190.96 | +0.22% |
| Week 5 | $132.05 | $160.48 | $195.04 | +0.27% |
| Week 6 | $129.68 | $160.57 | $198.81 | +0.32% |
| Week 7 | $127.55 | $160.65 | $202.35 | +0.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood and tissue tests and data sets in the United States and internationally. Its portfolio includes Guardant360 CDx, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal, a blood test that detects cancer at the molecular level; and Guardant360 Tissue, a molecular profiling test for tumor tissue.
The company also offers Shield blood testing for colorectal cancer screening and a family of platforms and services including GuardantINFINITY, GuardantOMNI, GuardantINFORM, and GuardantConnect, plus the Smart Platform for multiomic insights. In addition, Guardant Health provides development services and maintains a strategic collaboration with Nuvalent, Inc. for oncology drug development.
The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Guardant Health, Inc. trades at $156.17 per share and has a market cap of $20.71B, ranking 583 by market capitalization. The current price is complemented by a multi-year forecast that begins with a neutral 2026 outlook and progressively turns bullish in subsequent years. This trajectory suggests meaningful upside potential over the longer term.
A major floor 50.9% below — a decisive break under it would weaken the trend.
The nearest floor, 22.0% below — buyers have tended to step in here.
The nearest ceiling, 6.7% above — a clean break opens room to run.
A major ceiling 23.6% above — clearing it would confirm fresh momentum.
Key GH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $162.41 | Sell | $161.10 | Sell |
| MA 10 | $160.38 | Sell | $157.65 | Buy |
| MA 20 | $146.20 | Buy | $148.98 | Buy |
| MA 50 | $124.37 | Buy | $130.71 | Buy |
| MA 100 | $107.40 | Buy | $116.38 | Buy |
| MA 200 | $100.53 | Buy | $100.72 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.25 | Neutral |
| Stoch RSI (14) | 14.18 | Buy |
| CCI (20) | 65.12 | Neutral |
| Williams %R (14) | -25.56 | Info |
| MACD (12,26,9) | 0.39 | Buy |
| ROC (12) | 22.33 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 74.44 | Neutral |
| TRIX (15) | 1.25 | Buy |
| Awesome (5,34) | 24.12 | Buy |
| Ultimate (7,14,28) | 62.75 | Neutral |
| Momentum (10) | 17.11 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 160.51 | Sell |
| ADX (14) | 38.47 | Buy |
| ATR (14) | 4.76 | Info |
The near-term technical picture shows a bullish tilt with RSI(14) at 60, indicating strengthening momentum without overbought risk. The stock trades above the SMA50 of $121.32 and well above the SMA200 of $99.50, which is typically considered constructive for a positive short-term bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $78.60 | $160.05 | $229.26 | 0% | Neutral | |
| $189.42 | $242.62 | $330.95 | +52% | Bullish | |
| $215.88 | $286.19 | $407.66 | +79% | Bullish | |
| $218.40 | $297.97 | $438.99 | +86% | Bullish | |
| $259.36 | $362.99 | $550.09 | +127% | Bullish | |
| $286.63 | $410.63 | $637.76 | +157% | Bullish | |
| $319.47 | $467.79 | $742.66 | +192% | Bullish | |
| $417.00 | $623.31 | $1,009.37 | +289% | Bullish | |
| $474.38 | $723.13 | $1,192.52 | +352% | Bullish | |
| $512.25 | $795.73 | $1,334.56 | +397% | Bullish | |
| $804.64 | $1,363.04 | $2,452.44 | +752% | Bullish | |
| $1,333.82 | $2,634.16 | $5,245.09 | +15.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $78.60 | $160.05 | $196.10 | +0.00% |
| August 2026 | $136.13 | $161.61 | $197.68 | +0.97% |
| September 2026 | $134.62 | $161.18 | $199.77 | -0.27% |
| October 2026 | $141.25 | $170.35 | $213.50 | +5.69% |
| November 2026 | $146.56 | $177.86 | $225.00 | +4.41% |
| December 2026 | $147.22 | $179.69 | $229.26 | +1.03% |
Click any year to see its month-by-month GH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GH is projected to trade between $78.60 and $229.26, averaging $160.05 — a potential gain of 0% from today's $160.05. Price action looks broadly range-bound.
Guardant Health, Inc.'s 2027 outlook centres on $242.62, within a $189.42 to $330.95 range. That is up +52% on the projected 2026 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, GH could reach as high as $407.66, with a base case around $286.19 and support toward $215.88 — roughly +79% from $160.05. Momentum favours further upside here.
Expect GH to range from $218.40 to $438.99 through 2029. The $297.97 average target implies a +86% move from current prices. That is up +4% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The GH price prediction for 2030 points to an average of $362.99 (low $259.36, high $550.09) — a potential gain of +127% on today's $160.05. Momentum favours further upside here.
In 2031, GH is projected to trade between $286.63 and $637.76, averaging $410.63 — a potential gain of +157% from today's $160.05. That is up +13% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Guardant Health, Inc.'s 2032 outlook centres on $467.79, within a $319.47 to $742.66 range. That is up +14% on the projected 2031 average. That marks a +192% change versus current levels. Momentum favours further upside here.
By 2033, GH could reach as high as $1,009.37, with a base case around $623.31 and support toward $417.00 — roughly +289% from $160.05. Buyers look set to stay in control over this stretch.
Expect GH to range from $474.38 to $1,192.52 through 2034. The $723.13 average target implies a +352% move from current prices. That is up +16% on the projected 2033 average. Momentum favours further upside here.
The GH price prediction for 2035 points to an average of $795.73 (low $512.25, high $1,334.56) — a potential gain of +397% on today's $160.05. Buyers look set to stay in control over this stretch.
In 2040, GH is projected to trade between $804.64 and $2,452.44, averaging $1,363.04 — a potential gain of +752% from today's $160.05. That is up +71% on the projected 2035 average. Momentum favours further upside here.
Guardant Health, Inc.'s 2050 outlook centres on $2,634.16, within a $1,333.82 to $5,245.09 range. That is up +93% on the projected 2040 average. That marks a +15.5x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in GH today (≈ 6.248047 GH) could be worth
$16,458.33
+$15,458.33 (+1546%) by 2050 · US Dollar
Based on the average projected GH price of $2,634.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GHwould be worth at today's price.
$1,000 invested in GH on Jul 10, 2025 (≈ 19.496978 GH) would be worth
$3,120.49
+$2,120.49 (+212.0%) today · 3.12× · US Dollar
Based on a GH entry price of $51.29 vs. today's $160.05.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $167.98 | $952.79 | -4.7% |
| 1 month ago | $130.7 | $1,224.56 | +22.5% |
| 3 months ago | $78.6 | $2,036.26 | +103.6% |
| 6 months ago | $107.57 | $1,487.87 | +48.8% |
| 1 year ago | $51.29 | $3,120.49 | +212.0% |
| All time (5.0y) ago | $121.06 | $1,322.07 | +32.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GH forecast.
Our base-case forecast reaches $320.00 around 2030.
Implied market cap at $320.00: $42.43B
The multi-year forecast outlines a strong bullish trajectory beyond 2026. For 2026, the avg is $156.17 with a min of $78.60 and a max of $224.70, and a 0% ROI, indicating a neutral tone. Beginning in 2027, the outlook shifts higher with an avg of $240.11 and a 53.8% ROI, followed by 2028 at $283.59 (81.6%), 2029 at $295.44 (89.2%), and 2030 at $361.64 (131.6%).
The bullish trend continues through 2031 ($406.74, 160.4%), 2032 ($458.84, 193.8%), and 2033 ($616.68, 294.9%). By 2034 the avg is $718.84 (360.3%), 2035 $791.50 (406.8%), 2040 $1,347.25 (762.7%), and 2050 $2,635.58 (1587.6%). These figures point to substantial upside potential but remain subject to the usual uncertainties around long-range forecasts.
Tap a question to reveal the answer.
Avg $361.64; min $258.07; max $548.76; ROI 131.6%; sentiment bullish.
Forecast shows bullish sentiment from 2027 through 2050 with rising averages and high ROIs (e.g., 2027 avg $240.11, ROI 53.8%; 2050 avg $2,635.58, ROI 1587.6%). 2026 is neutral with an avg of $156.17 and ROI 0%.
Yes. In 2033, max $1,000.18; avg $616.68; min $411.90; sentiment bullish.
Current price $156.17; market cap $20.71B.
RSI(14) is 60; SMA50 is $121.32; SMA200 is $99.50; support is $119.85; resistance is $170.77; 30-day range is $125.53 to $194.29.
Guardant Health, Inc. Community Discussion
0Share your Guardant Health, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.